Home / News / Systagenix At Gargrave

Systagenix at Gargrave

History of Gargrave Facility
  • 1780 Original woollen mill built

  • 1924 Johnson & Johnson Limited established in the U.K.

  • 1934 Gargrave site acquired by Johnson & Johnson

  • 1960 Research & Development presence established

  • 1973 Major facility extension

  • 1992 Cobalt sterilisation unit commissioned

  • 1995 Gargrave designated European Operations Centre

  • 1997 Specialist biopolymers R&D group relocate to Gargrave

  • 2003 U.S. A.W.C. & Biocides relocated to Gargrave

  • 2004 Freeze Drying facility is validated

  • 2007 New Technology Centre opens

  • 2008 Johnson & Johnson divest Professional Wound Care business and Systagenix Wound Management established

  • 2009 Celebrating 75 years of Medical Device Manufacture


Total amount of major investments 2003 – 2009: $23.44MM


Gargrave Facility Workforce

Providing a broad range of skilled jobs in a rural economy

  • Manufacturing: 175
  • Engineering/Technology: 44
  • R&D, Regulatory & support functions: 112
  • Agency staff: 51
  • Total: 382

50 people with 25 years’ service & over

Supporting the local community

  • Community Action Group events
  • Supporting local charities
  • Supporting local schools and hospitals

Driving higher standard of care in the UK

  • One of the most penetrated markets in wound care
  • Gargrave continues to play a significant role

Sustaining UK’s strength in innovationCentre of Excellence for Wound Healing


2010-11-19

Právní upozornění Zásady ochrany osobních údajů © Copyright 2016, 2018, KCI Licensing, Inc. All rights reserved.